Zim Laboratories Limited (ZIMLAB) fundamentals
Zim Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ZIMLAB (ISIN INE518E01015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Zim Laboratories Limited does
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Valuation and market data
| Last close | ₹126.69 |
|---|---|
| Market capitalisation | ₹622 crore |
| Enterprise value | ₹649 crore |
| P/E (TTM) | 106.46 |
| Price to book | 2.10 |
| Price to sales (TTM) | 0.93 |
| Book value per share | ₹60.35 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Nov 25 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹386 crore | ₹8 crore | ₹6 crore | 1.19 |
| Mar 2025 | ₹385 crore | ₹18 crore | ₹12 crore | 2.50 |
| Mar 2024 | ₹373 crore | ₹24 crore | ₹17 crore | 3.54 |
| Mar 2023 | ₹405 crore | ₹35 crore | ₹24 crore | 5.01 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 30.3% |
|---|---|
| Foreign institutions (FII) | 0.2% |
| Mutual funds | 1.2% |
| Other domestic institutions | 0.0% |
| Retail and others | 68.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.